Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

Press/Media

Period	28 Feb 2023

Media coverage

Title	Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
Media name/outlet	Oncology Nursing News
Country/Territory	United States
Date	28/02/23
URL	ct.moreover.com/?a=50125873946&p=1gw&v=1&x=31Eh3wLDoBi6Noj8XYcNIA
Persons	Mauricio Burotto